NCT04409080: A trial that was reported late by Regeneron Pharmaceuticals
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT04409080 |
|---|---|
| Title | A Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 13, 2021 |
| Completion date | Oct. 17, 2024 |
| Required reporting date | Oct. 17, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Sept. 8, 2025 |
| Days late | None |